Pharmacoeconomics

Article	Citations
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?	205
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”	93
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling	84
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis	60
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment	54
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment	52
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	42
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting	39
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy	38
Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)	38
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	36
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children	33
Advancing Methods to Measure and Reward Healthcare Innovation	31
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned	28
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling	28
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)	28
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review	28
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy	28
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation	28
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS	27
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based	26
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions	25
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review	24
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA	24
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States	24

Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies	24
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment	24
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know	24
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review	24
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective	23
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada	23
Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap	22
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review	22
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes	20
The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations	20
Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey	19
A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries	19
Market Transparency in Medicine Pricing: Pathways to Fair Pricing	19
A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons	19
Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review	18
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition	18
The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review	18
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs	17
Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework	17
Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice	17
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia	17
Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)	17
Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations	17
Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program	17
Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators	17
A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)	16
Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies	16
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models	16
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry	15
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds	15
Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries	15
Acknowledgement to Referees	14
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Mye	13
Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia	13
Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents	13
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models	13
Comment on Keeney et al.’s “Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening”	13
A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates	13
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis	12
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection	12
Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria	12
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer	12
Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated	12
Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures	12
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis	12
Modelling the Cost-Effectiveness of Diagnostic Tests	12
Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)	12
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China	12
Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review	11
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom	11

A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework	11
How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review	11
Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability	11
Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”	11
Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study	11
Systematic Review of the Relative Social Value of Child and Adult Health	11
Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job Characteristics	11
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA	11
Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective	11
Economic Implications of Endometriosis: A Review	11
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments	10
A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper	10
The Costs of Dementia in Europe: An Updated Review and Meta-analysis	10
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments	10
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer	10
Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand	10
Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis	10
Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study	10
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review	10
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort	10
What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK	10
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review	10
Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations	10
Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision	10
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?	10
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias	9
Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer	9
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges	9
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel	9
Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation	9
Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods	9
Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L	9
Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses	9
A Value Set for the EQ-5D-Y-3L in the Netherlands	9
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study	9
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan	9
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meni	9
A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process	8
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time	8
Using AI in the Economic Evaluation of AI-Based Health Technologies	8
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study	8
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial	8
Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments	8
Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment	8
HTA Barriers for Conditional Approval Drugs	8
Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning	8
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom	8
Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target Populations	7
Valuing SF-6Dv2 in Australia Using an International Protocol	7
Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	7
PharmacoEconomics Supplement	7
Developing a Framework of Cost Elements of Socioeconomic Burden of Rare Disease: A Scoping Review	7
A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome	7
PharmacoEconomics	7
Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance	7
Economic Impact of Insufficient and Disturbed Sleep in the Workplace	7
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK	7
Correction: Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis	7
Does the Informal Carer Identification Method Matter? Evidence from Self-Declaration and Time Diary Approaches	7
Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States	7
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzer	7
Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening	7
Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments	7
Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs	6
A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement	6
China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population	6
Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Liv	6
Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment	6
NICE Approaches to Expert Opinion Evidence in Highly Specialised Technologies: Time to Change? Evidence Assessment Group Perspective	6
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression	6
How Much Better is Faster? Empirical Tests of QALY Assumptions in Health-Outcome Sequences	6
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US	6
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US	6
Cost-of-Illness of Skin Cancer: A Systematic Review	6
Efficiency of the EmERGE Pathway of Care in Five European HIV Centres	6
A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations	6
A Prototype Software Framework for Transferable Computational Health Economic Models and Its Early Application in Youth Mental Health	6
A Framework for the Fair Pricing of Medicines	6
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden	6
Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service	6

Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses	6
Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience	6
Incorporating Real Option Value in Valuing Innovation: A Way Forward	5
A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist	5
How Much Better is Faster? Value Adjustments for Health-Improvement Sequences	5
Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review	5
In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era	5
Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review	5
Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values	5
Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review	5
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework	5
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review	5
The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions	5
An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia	5
Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States	5
Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures	5
Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop	5
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe	5
Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease	5
Cost-Effectiveness of a Digital Leakage Notification System (Heylo™) for People with Ileostomies or Colostomies in the United Kingdom	5
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum	5
Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology	5
Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer	5
Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresect	5
Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework	5
An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?	5
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England	5
The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Sys	5
Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments	5
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrin	5
The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions	5
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial	4
Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation	4
Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review	4
Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review	4
Cost-Effectiveness Analysis Methods Used in Evaluations of Treatment for Cystic Fibrosis: A Scoping Review	4
Anchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A	4
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review	4
An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L	4
Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease	4
Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses	4
Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada	4
A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses	4
Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)	4
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Gro	4
In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives	4
The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life	4
A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects	4
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management	4
Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol	4
How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe	3
Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migr	3
A Comparison of PROPr and EQ-5D-5L Value Sets	3
Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L	3
Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA	3
Making Decision Models Fit for Purpose: The Importance of Ensuring Stakeholder Involvement	3
PharmacoEconomics Supplement	3
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States	3
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia	3
Artificial Intelligence as a New Research Ally? Performing AI-Assisted Systematic Literature Reviews in Health Economics	3
Estimating an EQ-5D-Y-3L Value Set for Brazil	3
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers	3
Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review	3
Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers	3
Cost Effectiveness of Pharmacological and Non-pharmacological Treatments for Depression in Low- and Middle-Income Countries: A Systematic Literature Review	3
Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario	3
Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?	3
Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?	3
Value-Based Healthcare in Practice: IDEATE, a Collaboration to Design and Test an Outcomes-Based Agreement for a Medicine in Wales	3
How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents	3
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	3
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Recept	3
Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid	3
EQ-5D-Y Population Norms for Japanese Children and Adolescents	3
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews	3
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic	3
Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention Strategy	3
Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review	3
Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States	3